AZRXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (22 9月 2021 @ 13:00):

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders...

Stats
本日の出来高	629 030
平均出来高	713 030
時価総額	3.43M
EPS	$-1.600 ( 2021-08-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.845
ATR14	$0.0530 (1.54%)

Insider Trading

Date	Person	Action	Amount	type
2021-09-09	Coelho Mary Theresa	Buy	10 310	Stock option (right to buy)
2021-08-11	Coelho Mary Theresa	Buy	0
2021-07-09	Pennington James	Buy	100 000	Stock option (right to buy)
2021-06-30	Schneiderman Daniel H	Buy	250 000	Stock option (right to buy)
2021-06-30	Schneiderman Daniel H	Buy	35 006	Stock option (right to buy)

INSIDER POWER
0.00
Last 81 transactions
Buy: 5 836 949 \| Sell: 2 173 162

ボリューム相関

長: -0.02 (neutral)

短: 0.65 (weak)

Signal:(72.656) Neutral

AzurRx BioPharma Inc 相関

10 最も正の相関
GAINL	0.969
HILS	0.956
ALR	0.948
MBIN	0.948
PSTX	0.929
WINT	0.928
RELI	0.925
TYRA	0.924
LFMDP	0.922
SATL	0.921

10 最も負の相関
BOCH	-0.962
SHSP	-0.934
TBIO	-0.928
CCSI	-0.927
EYE	-0.925
MMAC	-0.921
ACHC	-0.909
PPYAU	-0.908
SY	-0.902
RCM	-0.897

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

AzurRx BioPharma Inc 相関 - 通貨/商品

0.42
( neutral )

0.61
( weak )

0.00
( neutral )

0.40
( neutral )

0.32
( neutral )

-0.32
( neutral )

AzurRx BioPharma Inc 財務諸表

Annual	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5 902 903

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5 902 903

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-6.77

FY	2018
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-8.77

Financial Reports:

No articles found.

AzurRx BioPharma Inc

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).